Raymond James analyst Danielle Brill maintained a Hold rating on Global Blood Therapeutics (GBT – Research Report) yesterday. The company’s
Tag: GBT
H.C. Wainwright Thinks Global Blood Therapeutics’ Stock is Going to Recover
Global Blood Therapeutics (GBT – Research Report) received a Buy rating and a $75.00 price target from H.C. Wainwright analyst
Morgan Stanley Sticks to Their Hold Rating for Global Blood Therapeutics (GBT)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Global Blood Therapeutics (GBT –
Wedbush Keeps Their Buy Rating on Global Blood Therapeutics (GBT)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a
Raymond James Maintains Their Buy Rating on Global Blood Therapeutics (GBT)
In a report released today, Danielle Brill from Raymond James maintained a Buy rating on Global Blood Therapeutics (GBT –
Global Blood Therapeutics (GBT) Gets a Buy Rating from Oppenheimer
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to Global Blood Therapeutics (GBT – Research
Global Blood Therapeutics (GBT) Received its Third Buy in a Row
After Wedbush and Guggenheim gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy,